Hanna Vuornos appointed Director, People&Culture and as a member of the Management Team
Master of Social Sciences Hanna Vuornos (born 1978) has been appointed Director, People&Culture of the Revenio Group and as a member of the Group’s Management Team. Hanna will begin in her new position on August 16, 2021.
Hanna has more than 15 years of experience in strategic and operative HR in international organizations. Hanna is a renowned builder of partnerships, management practices, culture of leadership and operating models.
Hanna will move to her new position from her role as Director, HR Business Partner at Varian Medical Systems. Hanna has worked at Varian in Helsinki and Palo Alto, California. Her previous positions include HR development and management tasks at Telia, BearingPoint and Murata.
From August 16, 2021 onward, the members of the Management Team of Revenio Group are Revenio Group Corporation’s CEO Jouni Toijala (Chair), R&D Director of Imaging Devices Giuliano Barbaro, Operations Director Ari Isomäki, Sales and Marketing Director Tomi Karvo, CFO Robin Pulkkinen, R&D Director of Tonometers Mika Salkola and Director of Eye Care Solutions Kate Taylor, QA Director Heli Valtanen and Director, People&Culture Hanna Vuornos.
Revenio Group Corporation
Board of Directors
For further information, please contact:
CEO Jouni Toijala, tel. +358 50 484 0085 jouni.toijala@revenio.fi
CFO Robin Pulkkinen, tel. +358 50 505 9932 robin.pulkkinen@revenio.fi
www.revenio.fi
DISTRIBUTION:
Nasdaq Helsinki Oy
Financial Supervisory Authority Principal media
www.revenio.fi
Revenio Group in brief
Revenio is a leading company in ophthalmological devices and software solutions. Revenio Group’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), retinal imaging devices, and perimeters under the iCare brand. In addition, the Group’s eye care software platform Oculo brings together clinical communication, telehealth, remote patient monitoring, and data analytics capabilities.
Revenio Group comprises Revenio Group Corporation, Icare Finland Oy, Icare USA Inc., Revenio Italy S.R.L, CenterVue SpA, Revenio Research Oy, Revenio Australia Pty Ltd, Done Medical Oy and Oscare Medical Oy.
In 2020, the Group’s net sales totaled EUR 61.1 million and its operating profit amounted to EUR 17.1 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.
REVENIO GROUP OYJ 
